CompletedNCT00035230
About this title
A Study on the Safety and Efficacy of Topiramate in the Treatment of Patients With Bipolar I Disorder
Read the official source — NCT00035230What is this study about?This study evaluated the safety and effectiveness of Topiramate for people with bipolarity.
This study has finished and is no longer accepting participants.
Location not clearly listedBipolarityMedication studyAges 16+
- Countries
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
CompletedNCT06982651
Official study titleA Randomized, Double-Blind, Placebo-Parallel-Controlled Phase Ⅰ Clinical Trial of the Tolerability, Safety, Pharmacokinetics and Food Effects of MI078 Capsules in Single and Multiple Doses in Healthy Chinese Subjects
This study has finished and is no longer accepting participants.
In ChangshaDepressionMedication studyAges 18–45
- Countries
- China
- Sponsor
- Nanjing Minova Pharmaceutical Co., Ltd.
CompletedNCT05137704
Official study titleHealthcare Resources Utilization and Associated Costs of Adult ADHD in England
This study has finished and is no longer accepting participants.
In LondonADHDObservational studyAges 18+
- Countries
- United Kingdom
- Sponsor
- Takeda
CompletedACTRN12617000060347
Official study titleRandomised Controlled Trail testing the effectiveness of an Ecological Momentary Intervention (EMI) in adults with social anxiety symptoms
This study has finished and is no longer accepting participants.
In AustraliaAnxiety, DepressionInterventional studyAges 18+
- Countries
- Australia
- Sponsor
- Australian National University
CompletedNCT03666715
Official study titleA Multicenter Retrospective Study to Analyse the Impact of Treatment With Paliperidone Palmitate on Clinical Outcomes and Hospital Resource Utilization in Adult Patients With Schizophrenia in Portugal
This study has finished and is no longer accepting participants.
In PortoSchizophreniaObservational studyAges 18–55
- Countries
- Portugal
- Sponsor
- Janssen-Cilag Farmaceutica Ltda.
CompletedNCT04292197
Official study titleA Phase 1, Double-Blind, Randomized, Placebo-Controlled, Single/Multiple Day Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of 18- Methoxycoronaridine (18-MC HCl) Administered Orally to Normal Healthy Volunteers
This study has finished and is no longer accepting participants.
In PerthAddictionMedication studyAges 18–55
- Countries
- Australia
- Sponsor
- Definium Therapeutics US, Inc.
TerminatedNCT06618118
Official study titleA Phase 1 b Randomized, Double-blind, Placebo-Controlled, Experimental Medicine Study of Fosigotifator in Adults With Major Depressive Disorder
This study ended early.
Multiple locations, including Sherman OaksDepressionMedication studyAges 20–70
- Countries
- United States
- Sponsor
- AbbVie
CompletedNCT05145413
Official study titleA Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
This study has finished and is no longer accepting participants.
Multiple locations, including PhoenixSchizophreniaMedication studyAges 18–65
- Countries
- United States, United Kingdom, Bulgaria, + 5 others
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
CompletedNCT04659161
Official study titleA Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adults With DSM-5 Schizophrenia
This study has finished and is no longer accepting participants.
Multiple locations, including Little RockSchizophreniaMedication studyAges 18–65
- Countries
- United States
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
CompletedNCT04738123
Official study titleA Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adults With DSM-5 Schizophrenia
This study has finished and is no longer accepting participants.
Multiple locations, including BentonvilleSchizophreniaMedication studyAges 18–65
- Countries
- United States, Ukraine
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
WithdrawnNCT05268497
Official study titleAssessment of Feasibility of Using Clinician-Directed Cognitive Behavior Therapy Supplemented by a Digital Application in Conjunction With Esketamine (SPRAVATO®) in Participants With Treatment-Resistant Depression
This study was withdrawn before enrollment.
Multiple locations, including New HavenDepressionMedication studyAges 18–65
- Countries
- United States
- Sponsor
- Janssen Research & Development, LLC
CompletedNCT01788436
Official study titleAn Exploratory Study to Measure and Contrast Implicit and Explicit Learning Performance in Patients With Stable Schizophrenia and Young and Elderly Healthy Subjects
This study has finished and is no longer accepting participants.
In DuffelSchizophreniaBehavioural studyAges 18–85
- Countries
- Belgium
- Sponsor
- Janssen Research & Development, LLC